Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CULLINAN ONCOLOGY, INC.

(CGEM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2021 11/22/2021 11/23/2021 11/24/2021 11/26/2021 Date
19.47(c) 18.51(c) 19(c) 19.15(c) 18.22(c) Last
547 469 169 180 152 621 153 394 57 622 Volume
+1.04% -4.93% +2.65% +0.79% -4.86% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 18,9 M - -
Net income 2021 -52,8 M - -
Net cash position 2021 166 M - -
P/E ratio 2021 -14,9x
Yield 2021 -
Sales 2022 1,43 M - -
Net income 2022 -91,6 M - -
Net cash position 2022 191 M - -
P/E ratio 2022 -8,84x
Yield 2022 -
Capitalization 796 M 796 M -
EV / Sales 2021 33,3x
EV / Sales 2022 422x
Nbr of Employees 33
Free-Float 82,0%
More Financials
Company
Cullinan Oncology, Inc., formerly Cullinan Management, Inc. is a biopharmaceutical company. The Company is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The CompanyÔÇÖs lead candidate, CLN-081, is an orally available small molecule designed as an irreversible epidermal growth factor receptor (EGFR), inhibitor that is... 
More about the company
Ratings of Cullinan Oncology, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D+
More Ratings
All news about CULLINAN ONCOLOGY, INC.
11/22Cullinan Oncology to Participate in theáEvercore ISI 4th Annual HealthconX Conference
GL
11/09Cullinan Oncology Q3 Loss Narrows
MT
11/09CULLINAN ONCOLOGY, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
11/09Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2021 Financial Re..
PU
11/09Earnings Flash (CGEM) CULLINAN ONCOLOGY Reports Q3 Loss $-0.40
MT
11/09Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2021 Financial Re..
GL
11/09Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2021 Financial Re..
GL
10/18INSIDER SELL : Cullinan Oncology
MT
10/18Cullinan Oncology, Inc. Appoints Nadim Ahmed as President and Member of Board of Direct..
CI
10/18CONSOLIDATED GEMS : Cullinan Oncology Names Nadim Ahmed Chief Executive Officer
MT
10/18CULLINAN ONCOLOGY : Ahmed's appointment brings broad development and operational leadershi..
PU
10/18CULLINAN ONCOLOGY, INC. : Change in Directors or Principal Officers, Regulation FD Disclos..
AQ
10/18CULLINAN ONCOLOGY : Appoints Nadim Ahmed as Chief Executive Officer
AQ
10/18Cullinan Oncology, Inc. Announces Executive Changes
CI
09/20INSIDER SELL : Cullinan Oncology
MT
More news
News in other languages on CULLINAN ONCOLOGY, INC.
11/09La perte du troisième trimestre de Cullinan Oncology se réduit.
10/18VENTE D'INITIÉS : Cullinan Oncology
More news
Analyst Recommendations on CULLINAN ONCOLOGY, INC.
More recommendations
Chart CULLINAN ONCOLOGY, INC.
Duration : Period :
Cullinan Oncology, Inc. Technical Analysis Chart | CGEM | US2300311063 | MarketScreener
Technical analysis trends CULLINAN ONCOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 18,22 $
Average target price 51,75 $
Spread / Average Target 184%
EPS Revisions
Managers and Directors
Nadim Ahmed President, Chief Executive Officer & Director
Jeffrey Trigilio Chief Financial Officer
Anthony Adam Rosenberg Chairman
Patrick A. Baeuerle Chief Scientific Officer-Biologics
Thomas Ebeling Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CULLINAN ONCOLOGY, INC.0.00%796
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431